

Bacterial Bloodstream Infections in Cameroon: A Systematic Review and Meta-Analysis of Prevalence and Antibiotic Resistance

Moise Matakone^{1,2*‡}, Patrice Landry Koudoum^{2‡}, Ravalona Jessica Zemtsa³, Sen Claudine Henriette Ngomtcho^{2,4}, Isaac Dah^{1,5} and Michel Noubom^{2,7}

¹National Veterinary Laboratory (LANAVET), Yaoundé, Cameroon;

²Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon;

³Department of Biochemistry, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon;

⁴National Public Health Laboratory, Yaoundé, Cameroon;

⁵School of Veterinary Medicine and Science, University of Ngaoundéré, Ngaoundéré, Cameroon;

⁶Annex Regional Hospital of Dschang (ARHD), Dschang, Cameroon

***Corresponding author:**

Moise Matakone

National Veterinary Laboratory (LANAVET), Yaoundé, Cameroon

E-mail: moisematakone19@gmail.com

‡ These authors contributed equally.

Keywords: Bloodstream infection, bacteria, antibiotic resistance, Cameroon.

Running title: Bloodstream Infections in Cameroon

Words count: 2031

Number of figures: 2

Number of tables: 3

Abstract

Background: The paucity of data on the epidemiology of bloodstream infection (BSI) in low and middle-income countries (LMICs) limits its effective prevention and management. This review sought to determine the prevalence, bacteriological and antimicrobial resistance profiles of bacteria implicated in BSI in Cameroon.

Methods: PubMed and Google Scholar databases were searched to identify relevant articles, which were screened according to the PRISMA guidelines. The data were analysed using comprehensive meta-analysis software. The I^2 was used to evaluate heterogeneity between studies, Begg's and Egger's regression tests were used to evaluate publication bias, and random effects analysis was used to calculate the pooled prevalence.

Results: A total of 4223 blood cultures were obtained from the 10 included studies. The overall pooled prevalence of bacterial BSI was 26.31% (95% CI= 17.01%–38.35%). *Escherichia coli* (23.09%; 95% CI= 9.21%–47.05%), *Klebsiella* spp. (22.95%; 95% CI= 13.09%–37.07%), and *Staphylococcus aureus* (16.09%; 95% CI= 8.11%–29.43%) were the most common bacteria species. *E. coli* and *Klebsiella* spp. displayed the highest resistance to amoxicillin (82.65%; 95% CI= 63.25%–92.95% vs 86.42%; 95% CI= 55.90%–96.97%), amoxicillin + clavulanic acid (71.74%; 43.96–89.15% vs 73.06%; 95% CI= 38.70%–92.09%) and cotrimoxazole (76.22%; 95% CI= 51.33%–90.79% vs 65.81%; 95% CI= 45.08–81.86%). However, meropenem (26.73%; 95% CI= 20.76%–33.68%) and fosfomycin (14.85%; 95% CI= 9.07%–23.37%) were the least resistant in *E. coli* and *Klebsiella* spp., respectively. *Staphylococcus aureus* strains exhibited highest resistance to penicillin (84.37%; 95% CI= 68.13%–93.16%), erythromycin (44.80%; 95% CI= 33.37%–56.79%) and oxacillin (37.35%; 95% CI= 8.76%–78.74%) and lowest resistance to rifampicin (2.94%; 95% CI= 0.59%–13.39%), fusidic acid (6.73%; 95% CI= 2.55%–16.62%) and vancomycin (13.18%; 95% CI= 2.26%–49.86%).

Conclusion: This study reports a high prevalence of bacterial BSIs in Cameroon and the high resistance of these bacteria to common antibiotics. There is a pressing need to conduct BSI surveillance studies in all regions of Cameroon to generate data for evidence-based measures regarding BSI prevention and management.

Prospero registration number: CRD42023482760

Background

Bloodstream infection (BSI) is characterized by positive blood cultures in patients with systemic symptoms and signs of infection [1]. BSI can eventually lead to sepsis, which is a complication characterised by life-threatening organ dysfunction caused by a dysregulated host response to infection [1]. Sepsis and BSI are significantly associated with morbidity and mortality worldwide and represent major public health concerns [2]. According to the World Health Organization (WHO), sepsis accounted for approximately 20% of all global deaths in 2017, affected 49 million people, and resulted in 11 million fatalities [2, 3]. Vulnerable populations such as pregnant women, elderly persons, patients with severe comorbidities, newborns, and those in low-resource settings are disproportionately affected [4, 5]. Cases of sepsis and sepsis-related deaths in low and middle-income countries (LMICs) account for 85% of the global incidence of sepsis [3] and hospital mortality due to sepsis is estimated to be 19% for moderate sepsis and 39% for severe sepsis in sub-Saharan Africa (SSA) [6]. Bacteria, especially *Enterobacterales*, which include *Escherichia coli*, *Klebsiella* spp., and *Salmonella enterica*, and gram-positive cocci, such as *Staphylococcus aureus* and coagulase-negative *Staphylococci*, are major species implicated in BSI and sepsis [7, 8].

Inappropriate use of antibiotics is known to exacerbate the burden of antimicrobial resistance (AMR) in bacterial pathogens [9]. Globally, there is an increase in resistance to front-line antibiotics, including β -lactams, fluoroquinolones, aminoglycosides, and macrolides [10, 11]. Therefore, AMR is a major public health concern and is expected to be the leading cause of mortality by 2050, with 10 million deaths per year if no immediate measures are taken [12]. AMR is a serious challenge in hospital settings because it worsens the effects of bacterial infections in general, especially sepsis, from extended hospital stays to increased mortality [13, 14].

In Cameroon, the bacterial BSI and sepsis and the AMR rate of implicated bacteria are still poorly documented. Although some studies have been published, summarizing these available data is important for providing information on the context-specific epidemiology of BSIs in terms of aetiology and AMR rate and for directing future BSI and sepsis prevention and management efforts in Cameroon. Thus, in this review, we estimated the pooled proportion of culture-confirmed bacterial BSIs and their antimicrobial resistance (AMR) rates in Cameroon.

Methods

We conducted this systematic review and meta-analysis following the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines [15], and the protocol was registered in the Prospero database (Ref: CRD42023482760, available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023482760).

Search strategy

The National Library of Medicine database (MEDLINE) was searched through PubMed, along with Google Scholar and hand search. These databases were searched to find all articles reporting the prevalence of culture-confirmed bacteria-driven bloodstream infections. Library research was performed using Medical Subject Headings (MeSH) and keywords paired with Boolean operators (Figure S1 and Figure S2).

Eligibility criteria

Three authors independently searched the literature and evaluated the titles and abstracts of the papers. The articles included were studies that (1) reported culture-confirmed bacteria-driven bloodstream infections in Cameroon, (2) were published in peer-reviewed journals and (3) were published in English or French from 2010 to December 2023. Articles were excluded if (1) the full text was not assessable or (2) they were case reports or case series.

Study selection

After the literature search, we uploaded all the articles to the EndNote (version 20.6) database, and duplicates were removed. Two reviewers screened the titles and abstracts to assess whether specific inclusion criteria were met and non-relevant and those that did not meet the inclusion criteria were excluded. Disagreements on whether an article should be included were resolved by a third reviewer.

Data extraction

Two authors used a Microsoft Excel spreadsheet (version 2019) to extract the data from the included articles independently. The first author, publication year, region of study, study design, sample size, age of the study population, prevalence of BSIs, proportion of each bacteria causing BSIs and AMR rates of the bacteria groups were extracted. Inconsistencies were resolved through a group consensus.

Quality assessment

The quality of the included studies was assessed using the Joanna Briggs Institute revised Critical Appraisal Checklist [16]. The checklist was applied to each study to assess the eight items, with each item awarded a point for “yes”, and the final score for each article was added and fell between zero and eight. Any disagreements among the authors were resolved by consensus. A study was considered low risk if it scored ≥ 4 points.

Data analysis

We exported the extracted data to Comprehensive Meta-Analysis Software (version 3.0) for analysis. Begg and Egger’s regression tests were used to objectively assess publication bias, while a funnel plot was used to visualise this bias [17]. A p-value < 0.05 was considered to indicate statistical significance [18]. Cochrane Q statistics were used to assess the presence and magnitude of heterogeneity between studies. Heterogeneity was quantified using I^2 expressed as a percentage. Values of 75, 50 and 25% were considered high, medium and low heterogeneity respectively [19].

Results

Results of the literature search

The online database search from PubMed and Google Scholar yielded 329 articles and three articles through the hand search. Duplicates were removed, and 315 articles were included in the title and abstract screening. Finally, 27 articles were screened for full-text review, and 10 that met the study objectives were included (**Figure 1**).

Publication bias

When the BSI among study participants was analysed, a visual inspection of the funnel plot showed that there was no evidence of publication bias among the included studies (**Figure S3**). Similarly, the Egger’s regression intercept (4.89, 95% CI= -5.23–15.01, $p= 0.298$) and Begg test ($p= 0.79$) were not statistically significant.

Characteristics of the included studies

A total of 4223 blood cultures were obtained from the 10 included studies, 920 (21.79%) of which were performed exclusively in the paediatric population (children under 2 years old). The studies were conducted in two of the 10 regions of Cameroon and included patients from only two cities, Douala ($n=2547$; 60.31%) [20-22] and Yaoundé ($n=1676$; 39.69%) [23-29]. Most of the studies were cross-

sectional (n=08) [20, 22-25, 27-29], one was longitudinal [26] and one was retrospective [21], but all were of low risk. Only cross-sectional studies reported the age of the patients, which ranged from 0 to 92 years (Table S1).





Figure 1: PRISMA flow chart of the study selection process

Pooled prevalence and bacterial aetiology of bloodstream infections

The heterogeneity among the included studies was statistically significant ($I^2 = 97.63\%$; $p = 0.000$). Thus, we used a random effect model to calculate the pooled prevalence of culture-confirmed bacteria-driven bloodstream infections in Cameroon, and 95% confidence intervals (CIs) were represented on forest plots (Figure 2). Blood culture was performed for 4223 patients, and 888 were positive for a bacterial BSI. The bacterial BSI prevalence in this study ranged from 11.93% to 67.89%, and the overall pooled prevalence was 26.31% (95% CI= 17.01%–38.35%).



Note: Weights are from random effect analysis

BSI: Bloodstream infections

Figure 2: Forest plot of pooled prevalence of culture-confirmed bacterial bloodstream infections in Cameroon

The main bacterial groups reported in this study were *Enterobacterales*, *Staphylococci* and *Streptococci* (Table 1). Among the *Enterobacterales* group, *Escherichia coli* (23.09%; 95% CI= 9.21%–47.05%), was the most common bacteria, followed by *Klebsiella* spp. (22.95%; 95% CI= 13.09%–37.07%), *Enterobacter* spp. (7.66%; 95% CI= 4.46%–12.83%) and *Salmonella enterica* (7.15%; 95% CI= 3.68%–13.43%). Seven studies reported gram-positive cocci, of which *Staphylococcus aureus* was the most common (16.09%; 95% CI= 8.11%–29.43%), followed by *coagulase-negative Staphylococci* (10.85%; 95% CI= 3.15%–31.28%) and *Streptococcus* spp. (5.24%; 95% CI= 2.68%–10.00%).

Table 1: Pooled rate of major bacteria causing bloodstream infections in Cameroon

Bacterial species	Pooled rate (95%CI) from random effect	I ²	P-value	References
<i>E. coli</i>	23.09 (9.21–47.05)	96.42	0.000	[20, 21, 23-29]
<i>Klebsiella</i> spp.	22.95 (13.09–37.07)	83.02	0.000	[20, 21, 24, 26-29]
<i>Enterobacter</i> spp.	8.06 (4.96–12.83)	31.74	0.186	[20, 21, 24, 26-29]
<i>Salmonella enterica</i>	7.15 (3.68–13.43)	51.22	0.056	[20, 21, 24, 26-29]
<i>Acinetobacter</i> spp.	3.74 (2.07–6.66)	23.80	0.247	[20, 21, 24, 26-29]
<i>Pseudomonas</i> spp.	3.17 (1.96–5.07)	0.00	0.948	[20, 21, 24, 26-29]
<i>Staphylococcus aureus</i>	16.09 (8.11–29.43)	81.05	0.000	[20, 21, 24, 26-29]
<i>Coagulase negative Staphylococci</i>	10.85 (3.15–31.28)	93.82	0.000	[20, 21, 24, 26-29]
<i>Streptococcus</i> spp.	5.24 (2.68–10.00)	50.33	0.060	[20, 21, 24, 26-29]

Antimicrobial resistance rates of bacterial BSIs

This study reported only the pooled AMR rate of the most represented bacteria in each group. Overall, both *E. coli* and *Klebsiella* spp. displayed the highest resistance to amoxicillin (82.65%; 95% CI=

63.25%–92.95% vs 86.42%; 95% CI= 55.90%–96.97%), amoxicillin + clavulanic acid (71.74%; 43.96–89.15% vs 73.06%; 95% CI= 38.70%–92.09%) and cotrimoxazole (76.22%; 95% CI= 51.33%–90.79% vs 65.81%; 95% CI= 45.08–81.86%). Additionally, resistance to third and fourth-generation cephalosporins and monobactam was high among *E. coli* isolates: cefotaxime, 46.46% (95% CI= 26.77%–67.31%); ceftazidime, 49.92% (95% CI= 22.54%–70.32%); cefepime, 51.53% (95% CI= 40.92%–62.00%); aztreonam, 49.95% (95% CI= 40.59%–59.31%); *Klebsiella* spp isolates: cefotaxime, 40.98% (95% CI= 19.41%–66.69%); ceftazidime, 45.14% (95% CI= 16.76%–77.08%); and aztreonam, 54.25% (95% CI= 34.16%–73.04%). However, meropenem (26.73%; 95% CI= 20.76–33.66%) and fosfomycin (14.85%; 95% CI= 9.07%–23.37%) were the most effective against *E. coli* and *Klebsiella* spp., respectively (**Table 2**).

Table 2: Pooled antibiotic resistance rate of the most represented gram-negative bacilli isolated from bloodstream infections in Cameroon

Antibiotics	Pooled AMR rate from random model (95% CI)					
	<i>E. coli</i>	I ² (p-value)	N° isolates tested	<i>Klebsiella</i> spp.	I ² (p-value)	N° studies
Amoxicillin	82.65 (63.25–92.95)	80.60 (0.000)	275	86.42 (55.90–96.97)	65.68 (0.002)	107
Amoxicillin + clavulanic acid	71.74 (43.96–89.15)	91.69 (0.000)	276	73.06 (38.70–92.09)	73.34 (0.024)	99
Cefotaxime	46.46 (26.77–67.31)	91.25 (0.000)	263	40.98 (19.41–66.69)	65.20 (0.056)	99
Ceftazidime	49.92 (22.54–70.32)	87.69 (0.000)	274	45.14 (16.76–77.08)	77.92 (0.011)	99
Cefepime	51.53 (40.92–62.00)	41.50 (0.181)	187	NA	NA	NA
Cefoxitin	33.19 (18.55–52.01)	82.56 (0.000)	281	35.80 (19.48–56.25)	46.74 (0.131)	107
Aztreonam	49.95 (40.59–59.31)	0.00 (0.806)	108	54.25 (34.16–73.04)	0.00 (0.521)	24
Meropenem	26.73 (20.76–33.68)	0.00 (0.501)	180	NA	NA	NA
Amikacin	37.54 (18.66–61.15)	89.07 (0.000)	274	26.75 (6.12–67.16)	76.10 (0.009)	107
Gentamycin	49.48 (37.34–61.68)	61.89 (0.022)	281	50.07 (31.65–68.48)	47.64 (0.106)	115
Ciprofloxacin	41.73 (32.62–51.45)	21.87 (0.275)	191	56.52 (29.94–79.81)	62.49 (0.031)	115
Fosfomycin	NA	NA	NA	14.85 (9.07–23.37)	0.00 (0.728)	99
Nalidixic acid	34.60 (28.10–41.73)	0.00 (0.968)	185	NA	NA	NA
Cotrimoxazole	76.22 (51.33–90.79)	84.67 (0.000)	275	65.81 (45.08–81.86)	56.12 (0.077)	107

Staphylococcus aureus was highly resistant to penicillin (84.37%; 95% CI= 68.13%–93.16%), erythromycin (44.80%; 95% CI= 33.37%–56.79%) and oxacillin (37.35%; 95% CI= 8.76%–78.74%). However, a low percentage of *Staphylococcus aureus*-resistant strains was detected for non- β -lactam antibiotics, including rifampicin (2.94%; 95% CI= 0.59%–13.39%), fusidic acid (6.73%; 95% CI= 2.55%–16.62%), and vancomycin (13.18%; 95% CI= 2.26%–49.86%). In the CONS group, a high percentage of strains were resistant to penicillin (89.91%; 95% CI= 65.95%–97.62%), cotrimoxazole

(56.88%; 95% CI= 31.93%–78.78%) and oxacillin (50.70%; 95% CI= 24.97%–76.07%), while rifampicin (11.13%; 95% CI= 4.46%–25.16%) and cefoxitin (14.87%; 95% CI= 1.08%–73.62%) (**Table 3**).

Discussion

This review aimed to determine the pooled prevalence of bacterial BSIs and the AMR rates of implicated bacteria in Cameroon. The 10 studies selected for this review described 4223 blood cultures, and the overall pooled prevalence of BSI was 26.31%. This prevalence is higher than those reported in Africa by Reddy *et al.* (2010) and in Africa and Asia by Marchello *et al.* (2019), which were 7.4% and 10.8%, respectively [30, 31]. However, studies conducted in Ethiopia by Bitew *et al.* (2023), Legese *et al.* (2022) and Abebe *et al.* (2021) documented a similar prevalence of BSI [32–34]. The observed difference in this review may be due to the small sample size of many included studies [20, 22, 26, 27] and their study design.

Table 3: Pooled antibiotic resistance rate of the most represented Staphylococci causing bloodstream infections in Cameroon

Antibiotics	Pooled AMR rate from random model (95% CI)					
	<i>Staphylococcus aureus</i>	I ² (p-value)	N° isolates tested	<i>Coagulase negative Staphylococci</i>	I ² (p-value)	N° studies
Penicillin	84.37 (68.13–93.16)	39.86 (0.197)	61	89.91 (65.95–97.62)	66.56 (0.050)	93
Oxacillin	37.35 (8.76–78.74)	88.19 (0.004)	61	50.70 (24.97–76.07)	83.81 (0.002)	93
Cefoxitin	18.85 (1.16–82.07)	81.51 (0.020)	28	14.87 (1.08–73.62)	85.97 (0.008)	71
Gentamycin	18.85 (1.16–8.3)	81.51 (0.020)	28	36.67 (18.66–59.37)	76.23 (0.015)	93
Erythromycin	44.80 (33.37–56.79)	0.00 (0.892)	67	46.81 (27.28–67.37)	73.82 (0.022)	93
Lincomycin	25.69 (3.96–74.33)	90.21 (0.001)	61	42.05 (32.24–52.53)	2.26 (0.359)	93
Rifampicin	2.94 (0.59–13.39)	0.00 (0.450)	61	11.13 (4.46–25.16)	40.10 (0.196)	51
Tetracycline	28.04 (5.81–71.12)	84.06 (0.002)	67	41.71 (26.95–58.12)	56.10 (0.103)	93
Cotrimoxazole	27.26 (14.90–44.51)	35.99 (0.211)	61	56.88 (31.93–78.78)	81.37 (0.005)	93
Vancomycin	13.18 (2.26–49.86)	66.72(0.050)	67	30.40 (14.37–53.20)	63.64 (0.064)	93
Fusidic acid	6.73 (2.55–16.62)	0.00(0.637)	61	25.46 (17.44–35.58)	1.29 (0.363)	93

The study revealed that *Enterobacterales*, including *Escherichia coli* (23.09%) and *Klebsiella* spp. (22.95%), were the leading bacteria implicated in BSI. Studies conducted in several low and middle-income countries have demonstrated the strong implication of these bacteria in bloodstream infections and sepsis, especially in hospital settings [10, 34, 35]. However, these results contradict those recorded by Wattal *et al.* (2020) and Reddy *et al.* (2010), where *Salmonella* spp. were the leading cause of BSI

and sepsis [11, 30]. This contradiction might be due to the differences in the bacterial identification methods used, which are poorly described in some studies and can vary considerably depending on the laboratory [20, 21, 26]. Moreover, the observed contrast may be due to the differences in origins (community vs hospital) of bacteria driving BSIs. *Salmonella* spp. has been highly associated with community-acquired BSIs while *Escherichia coli* and *Klebsiella* spp. are to hospital-acquired BSIs [7, 30]. This may suggest that a greater share of BSIs reported in this review is of nosocomial origin. The most frequent *Enterobacterales* reported in this review exhibited high resistance to β -lactam antibiotics, especially third- and fourth-generation cephalosporins and monobactam. This might indicate the production of β -lactamases, particularly extended-spectrum β -lactamase enzymes, by most of these bacteria even though most of the included studies failed to report resistance phenotypes.

Limitations

The statements and conclusions in this review cannot be generalised to Cameroon, as the included studies investigated only two regions and some were limited by small sample sizes. Additionally, the study was unable to determine whether the BSI was community or hospital-acquired. Finally, the study failed to report AMR among several bacteria or the resistance phenotypes of the implicated bacteria. Notwithstanding, this review provides the most comprehensive data regarding bacterial BSI prevalence and AMR epidemiology in Cameroon.

Conclusion

The prevalence of bacterial bloodstream infection in this study was elevated. *Enterobacterales*, including *Klebsiella* spp. and *Escherichia coli*, and gram-positive cocci, particularly *Staphylococcus aureus*, remain the leading causes of bloodstream infection. Antibiotic resistance was greater for β -lactams in both *Enterobacterales* and gram-positive cocci. This study may help clinicians optimise their antibiotic prescription protocols for the early management of bacterial bloodstream infections in the absence of antibiotic susceptibility testing results. This review also calls for researchers to expend more effort to produce AMR data to permit policymakers and stakeholders to better manage and prevent bloodstream infection in Cameroon.

List of abbreviations

AMR: Antimicrobial Resistance

BSI: Bloodstream Infections

257 **Declarations**

258 **Ethics approval and consent to participate**

259 Not applicable

260 **Consent for publication**

261 Not applicable

262 **Availability of data and materials**

263 The datasets generated and/or analysed during the current study are available from the
264 corresponding author upon reasonable request.

265 **Competing interests**

266 The authors declare no conflicts of interest.

267 **Funding**

268 The study was not funded.

269 **Author contributions**

270 MM conceived and designed the study. MM and PLK coordinated the literature search. PKL, RJZ and
271 MM undertook the data extraction, quality assessment and statistical analysis. MM, PLK, and RJZ
272 prepared the first draft of the manuscript. ID, SCHN and MN critically reviewed the manuscript. All the
273 authors read and approved the final version of the manuscript.

274 **Acknowledgements**

275 Not applicable

276 **References**

- 277 [1]. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, *et al.* The
278 Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *Jama*.
279 2016;315(8):801-10. <https://doi.org/10.1001/jama.2016.0287>
- 280 [2]. WHO. Global report on the epidemiology and burden of sepsis: Current evidence, identifying
281 gaps and future directions. 2020.
- 282 [3]. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, *et al.* Global, regional,
283 and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease
284 Study. *Lancet*. 2020;395(10219):200-11. [https://doi.org/10.1016/s0140-6736\(19\)32989-7](https://doi.org/10.1016/s0140-6736(19)32989-7)

285 [4]. Cheng AC, West TE, Limmathurotsakul D, Peacock SJ. Strategies to reduce mortality from
 286 bacterial sepsis in adults in developing countries. PLoS Med. 2008;5(8):e175.
 287 <https://doi.org/10.1371/journal.pmed.0050175>

288 [5]. Rhee C, Jones TM, Hamad Y, Pande A, Varon J, O'Brien C, *et al.* Prevalence, Underlying
 289 Causes, and Preventability of Sepsis-Associated Mortality in US Acute Care Hospitals. JAMA Netw
 290 Open. 2019;2(2):e187571. <https://doi.org/10.1001/jamanetworkopen.2018.7571>

291 [6]. Lewis JM, Feasey NA, Rylance J. Aetiology and outcomes of sepsis in adults in sub-Saharan
 292 Africa: a systematic review and meta-analysis. Critical Care. 2019;23(1):212.
 293 <https://doi.org/10.1186/s13054-019-2501-y>

294 [7]. Timsit JF, Ruppé E, Barbier F, Tabah A, Bassetti M. Bloodstream infections in critically ill
 295 patients: an expert statement. Intensive Care Med. 2020;46(2):266-84. [https://doi.org/10.1007/s00134-](https://doi.org/10.1007/s00134-020-05950-6)
 296 [020-05950-6](https://doi.org/10.1007/s00134-020-05950-6)

297 [8]. Mun SJ, Kim S-H, Kim H-T, Moon C, Wi YM. The epidemiology of bloodstream infection
 298 contributing to mortality: the difference between community-acquired, healthcare-associated, and
 299 hospital-acquired infections. BMC Infectious Diseases. 2022;22(1). [https://doi.org/10.1186/s12879-](https://doi.org/10.1186/s12879-022-07267-9)
 300 [022-07267-9](https://doi.org/10.1186/s12879-022-07267-9)

301 [9]. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic
 302 resistance. Nat Rev Microbiol. 2015;13(1):42-51. <https://doi.org/10.1038/nrmicro3380>

303 [10]. Ombelet S, Kpossou G, Kotchare C, Agbobli E, Sogbo F, Massou F, *et al.* Blood culture
 304 surveillance in a secondary care hospital in Benin: epidemiology of bloodstream infection pathogens
 305 and antimicrobial resistance. BMC Infect Dis. 2022;22(1):119. [https://doi.org/10.1186/s12879-022-](https://doi.org/10.1186/s12879-022-07077-z)
 306 [07077-z](https://doi.org/10.1186/s12879-022-07077-z)

307 [11]. Wattal C, Goel N. Pediatric Blood Cultures and Antibiotic Resistance: An Overview. Indian J
 308 Pediatr. 2020;87(2):125-31. <https://doi.org/10.1007/s12098-019-03123-y>

309 [12]. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. 2016.
 310 <https://apo.org.au/node/63983>

311 [13]. Chaurasia S, Sivanandan S, Agarwal R, Ellis S, Sharland M, Sankar MJ. Neonatal sepsis in
 312 South Asia: huge burden and spiralling antimicrobial resistance. Bmj. 2019;364:k5314.
 313 <https://doi.org/10.1136/bmj.k5314>

314 [14]. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, *et al.* Global
315 burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet*.
316 2022;399(10325):629-55. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0)

317 [15]. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, *et al.* The PRISMA
318 2020 statement: An updated guideline for reporting systematic reviews. *PLoS Med*.
319 2021;18(3):e1003583. <https://doi.org/10.1371/journal.pmed.1003583>

320 [16]. Joanna Briggs Institute. Critical-Appraisal-Tools—Critical Appraisal Tools I JBI. 2022. Available
321 online: <https://jbi.global/critical-appraisal-tools> (accessed on 07 November 2023).

322 [17]. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple,
323 graphical test. *Bmj*. 1997;315(7109):629-34. <https://doi.org/10.1136/bmj.315.7109.629>

324 [18]. Fletcher J. What is heterogeneity and is it important? *Bmj*. 2007;334(7584):94-6.
325 <https://doi.org/10.1136/bmj.39057.406644.68>

326 [19]. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses.
327 *Bmj*. 2003;327(7414):557-60. <https://doi.org/10.1136/bmj.327.7414.557>

328 [20]. Kemeze S, Moudze B, Chiabi A, Eposse C, Kaya A, Mbangué M, *et al.* Profil clinique et
329 bactériologique des infections néonatales bactériennes à l'Hôpital Laquintinie de Douala, Cameroun.
330 *The Pan African Medical Journal*. 2016;23.

331 [21]. Okalla Ebongue C, Mefo'o JP, Te N, Moukoko E, Adiogo D, Beyiha G. Profil Bactériologique et
332 sensibilité aux antibiotiques des isolats d'hémoculture (2006 – 2011) à Douala, Cameroun. *Revue*
333 *Malienne d'Infectiologie et de Microbiologie*. 2014;2. <https://doi.org/10.53597/remim.vi2.365>

334 [22]. Teghonong J, Okalla Ebongue C, Yadufashije C, Kojom LP, Adiogo D. Phenotypic
335 Characteristics of *Klebsiella pneumoniae* Extended Spectrum β -Lactamases Producers Isolated in
336 Hospitals in the Littoral Region, Cameroon. *European Journal of Clinical Microbiology*. 2020;6:9-13.
337 <https://doi.org/10.11648/j.ejcbcs.20200601.13>

338 [23]. Carole Suzie Lacmago Titsamp HKG, Simon Ngamli Fewou. Bloodstream infections initiated
339 by ESBL-producing *Escherichia coli* in neonates and infants at two hospitals in Yaoundé, Cameroon.
340 *International Journal of Biological and Chemical Sciences*. 2021;15(3).
341 <https://doi.org/10.4314/ijbcs.v15i3.27>

342 [24]. Chiabi A, Djoupomb M, Mah E, Nguefack S, Mbuagbaw L, Zafack J, *et al.* The clinical and
343 bacteriological spectrum of neonatal sepsis in a tertiary hospital in yaounde, cameroon. Iran J Pediatr.
344 2011;21(4):441-8.

345 [25]. Djuikoue CI, Djouela Djoulako PD, Wouambo RK, Lacmago ST, Dayomo A, Kamga HG, *et al.*
346 Prevalence of Escherichia coli Producing Extended Spectrum Beta-Lactamase (ESBL) Driven
347 Septicaemia in Children Aged 0–2 Years in Two Districts Hospitals in Yaounde, Cameroon. Bacteria.
348 2022;1(4):294-301.

349 [26]. Nouetchognou JS, Ateudjieu J, Jemea B, Mesumbe EN, Mbanya D. Surveillance of nosocomial
350 infections in the Yaounde University Teaching Hospital, Cameroon. BMC Res Notes. 2016;9(1):505.
351 <https://doi.org/10.1186/s13104-016-2310-1>

352 [27]. Yimtchi LCN, Pokam BDT, Baiye AW, Betbeui AC, Gonsu HK, Djakissam W. Antibiotic
353 Susceptibility Patterns of Bacteria Associated with Sepsis among Hospitalized Patients in the Yaoundé
354 University Teaching Hospital—Cameroon. Open Journal of Medical Microbiology. 2023;13(1):101-15.

355 [28]. Kamga H, Njunda A, Nde P, Assob J, Nsagha D, Weledji P. Prevalence of septicaemia and
356 antibiotic sensitivity pattern of bacterial isolates at the University Teaching Hospital, Yaoundé,
357 Cameroon. African Journal of Clinical and Experimental Microbiology. 2011;12(1).

358 [29]. Zefack JT, Ambe NF, Bobga TP, Ketum AS, Awambeng DN, Kelly CN, *et al.* Bacteriological
359 Profile and Antimicrobial Sensitivity Pattern of Blood Culture Isolates among Septicemia Suspected
360 Patients in the University Teaching Hospital (UTH) Yaoundé, Cameroon. 2020.

361 [30]. Reddy EA, Shaw AV, Crump JA. Community-acquired bloodstream infections in Africa: a
362 systematic review and meta-analysis. The Lancet infectious diseases. 2010;10(6):417-32.

363 [31]. Marchello CS, Dale AP, Pisharody S, Rubach MP, Crump JA. A Systematic Review and Meta-
364 analysis of the Prevalence of Community-Onset Bloodstream Infections among Hospitalized Patients
365 in Africa and Asia. Antimicrob Agents Chemother. 2019;64(1). <https://doi.org/10.1128/aac.01974-19>

366 [32]. Bitew A, Adane A, Abdeta A. Bacteriological spectrum, extended-spectrum β -lactamase
367 production and antimicrobial resistance pattern among patients with bloodstream infection in Addis
368 Ababa. Scientific Reports. 2023;13(1). <https://doi.org/10.1038/s41598-023-29337-x>

- 369 [33]. Abebe W, Tegene B, Feleke T, Sharew B. Bacterial Bloodstream Infections and their
370 Antimicrobial Susceptibility Patterns in Children and Adults in Ethiopia: a 6-Year Retrospective Study.
371 Clin Lab. 2021;67(11). <https://doi.org/10.7754/Clin.Lab.2021.210224>
- 372 [34]. Legese MH, Asrat D, Swedberg G, Hasan B, Mekasha A, Getahun T, *et al.* Sepsis: emerging
373 pathogens and antimicrobial resistance in Ethiopian referral hospitals. Antimicrobial Resistance &
374 Infection Control. 2022;11(1):83. <https://doi.org/10.1186/s13756-022-01122-x>
- 375 [35]. Solomon S, Akeju O, Odumade OA, Ambachew R, Gebreyohannes Z, Van Wickle K, *et al.*
376 Prevalence and risk factors for antimicrobial resistance among newborns with gram-negative sepsis.
377 PLOS ONE. 2021;16(8):e0255410. <https://doi.org/10.1371/journal.pone.0255410>

Supplementary figures

(antimicrobial OR antibacterial OR antibiotics OR antibiotiques OR antimicrobial resistance OR antibiotic resistance OR multiresistance OR multidrug resistance) OR (bacteria OR bactéries OR *Enterobacterales* OR *Enterobacteriaceae* OR entérobactéries OR *Escherichia coli* OR *E. coli* OR *Klebsiella* OR *Staphylococcus* OR *Salmonella* OR Typhoid OR *Enterobacter* OR *Pseudomonas* OR *Acinetobacter* OR *Streptococcus* OR coagulase negative OR gram negative OR gram positive) AND (bloodstream infections OR hémoculture OR hemoculture OR sepsis OR septicemia OR septicæmia OR septicémie OR neonatal sepsis) AND (Cameroon OR Cameroun).

Figure S1: Search terms used to identify relevant literature from PubMed

allintitle: Cameroon OR Cameroun "bloodstream infections" OR hémoculture OR hemoculture OR hémocultures OR bacteremia OR bactereamia OR bactériémie OR sepsis OR septicemia OR septicæmia OR septicémie OR "neonatal sepsis" OR antimicrobial OR antibacterial OR antibiotics OR antibiotiques OR "antimicrobial resistance" OR "antibiotic resistance" OR multiresistance OR "multidrug resistance" OR bacteria OR bactéries OR enterobacterales OR enterobacteriaceae OR entérobactéries.

Figure S2: Search terms used to identify relevant literature from Google Scholar




Figure S3: Funnel plot of standard error by logit event rate









Figure S4: Forest plots of pooled rates of major gram-negative bacilli causing bloodstream infections in Cameroon






Figure S5: Forest plots of pooled rates of major gram-positive cocci causing bloodstream infections in Cameroon

Supplementary table

Table S1: Summary characteristics of studies included in the meta-analysis

Study period	Study type	City	Population size	Age range	Prevalence n (%)	Quality	Authors/Year of publication
January-April 2018	Cross-sectional	Yaoundé	255	0 – 82 years	65 (25.49)	Low-risk	Zefack et al., 2020
August-October 2017	Cross-sectional	Yaoundé	298	0 – 48 weeks	129 (43.29)	Low-risk	Titsamp et al., 2021
August 2019-March 2020	Cross-sectional	Yaoundé	300	0 – 2 years	130 (43.33)	Low-risk	Djuikoue et al., 2022
March-June 2015	Cross-sectional	Douala	104	0 – 28 days	17 (16.35)	Low-risk	Kemeze et al., 2016
September 2013 -March 2014	Longitudinal	Yaoundé	59	NA	12 (20.34)	Low-risk	Nouetchognou et al., 2016
2006-2011	Retrospective	Douala	2334	NA	299 (12.81)	Low-risk	Ebongue et al., 2014
January-June 2010	Cross-sectional	Yaoundé	396	0 – >76 years	112 (28.28)	Low-risk	Kanga et al., 2011
November 2008-May 2009	Cross-sectional	Yaoundé	218	0 – 28 days	26 (11.93)	Low-risk	Chiabi et al., 2011
November 2021-March 2022	Cross-sectional	Yaoundé	150	10 – 92 years	24 (16.00)	Low-risk	Yimtchi et al., 2023
January 2016- February 2017	Cross-sectional	Douala	109	>1 – 71 years	74 (67.89)	Low-risk	Teghonong et al., 2020